BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 32059024)

  • 21. Identifying the Cellular Interactome of Epstein-Barr Virus Lytic Regulator Zta Reveals Cellular Targets Contributing to Viral Replication.
    Zhou Y; Heesom K; Osborn K; AlMohammed R; Sweet SM; Sinclair AJ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.
    Ellis AL; Wang Z; Yu X; Mertz JE
    J Virol; 2010 Jun; 84(12):6139-52. PubMed ID: 20375168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.
    Trivedi P; Spinsanti P; Cuomo L; Volpe M; Takada K; Frati L; Faggioni A
    J Virol; 2001 May; 75(10):4929-35. PubMed ID: 11312367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
    Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.
    Szymula A; Palermo RD; Bayoumy A; Groves IJ; Ba Abdullah M; Holder B; White RE
    PLoS Pathog; 2018 Feb; 14(2):e1006890. PubMed ID: 29462212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
    Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
    PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus.
    Yu X; Wang Z; Mertz JE
    PLoS Pathog; 2007 Dec; 3(12):e194. PubMed ID: 18085824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.
    Cancian L; Bosshard R; Lucchesi W; Karstegl CE; Farrell PJ
    PLoS Pathog; 2011 Jul; 7(7):e1002164. PubMed ID: 21857817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BZLF1 transcript variants in Epstein-Barr virus-positive epithelial cell lines.
    Needham J; Adamson AL
    Virus Genes; 2019 Dec; 55(6):779-785. PubMed ID: 31552622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
    Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
    Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes.
    Singh DR; Nelson SE; Pawelski AS; Cantres-Velez JA; Kansra AS; Pauly NP; Bristol JA; Hayes M; Ohashi M; Casco A; Lee D; Fogarty SA; Lambert PF; Johannsen EC; Kenney SC
    PLoS Pathog; 2022 Oct; 18(10):e1010868. PubMed ID: 36190982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member.
    Liu S; Liu P; Borras A; Chatila T; Speck SH
    EMBO J; 1997 Jan; 16(1):143-53. PubMed ID: 9009275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
    Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
    J Virol; 2018 May; 92(9):. PubMed ID: 29467311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
    Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
    Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.
    McDonald C; Karstegl CE; Kellam P; Farrell PJ
    J Gen Virol; 2010 Mar; 91(Pt 3):622-9. PubMed ID: 19923262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Rta in B Lymphocytes during Epstein-Barr Virus Latency.
    Hwang SP; Huang LC; Wang WH; Lin MH; Kuo CW; Huang HH; Chang LK
    J Mol Biol; 2020 Sep; 432(19):5227-5243. PubMed ID: 32710985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.